Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors
US11697650B2 · kind B2 · utility
0Cited by
1References
61Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 11, 2022 |
| Grant date | Jul 11, 2023 |
| Priority date | — |
| Expiry date | Mar 11, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is generally directed to inhibitors of BCL-2 proteins useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I):
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.